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preliminary studies of an animal model of ehrlichiosis [8]. Immu-
noblots of sera from Balb/C mice experimentally infected with
Ehrlichia microti, but not B. burgdorferi, demonstrated reactivity
to OspC, OspA, 36, 38, 93 kDa, and other antigens [8].
Contrary to the assertion of Gunthard et al., a negative serology
for Ehrlichia equi does not exclude coinfection with Ehrlichia. We
have seen seronegative patients for whom the clinical diagnosis was
supported in other ways (e.g., cultures). These authors did not report
the results of a culture for Ehrlichia or of a PCR assay. Conclusions
concerning the sensitivity of serology for E. equi in the diagnosis of
HGE (for both doxycycline-treated patients and untreated patients)
should not be drawn until more data become available.
Leukopenia and thrombocytopenia are common findings in pa-
tients with ehrlichiosis [9] and have been observed in 71% of
Slovenian patients during the initial phase of tick-borne encephali-
tis [10]. Babesiosis is also known to cause these hematologic ab-
normalities. Any of these three illnesses could have coexisted with
B. burgdorferi infection [9] in the patient of Gunthard et al. Case
reports such as theirs should serve as an impetus to study the
prevalence of HGE and babesiosis in those parts of Europe where
Ixodes ticks are already known to be vectors for B. burgdorferi
and the tick-borne encephalitis virus.
We are concerned that the addition of another protean manifestation
of Lyme borre1iosis, based on anecdotal evidence, will contribute
to the growing mythology surrounding this illness. Where possible,
microbiological confirmation by culture should be used to define the
spectrumofB. burgdorferi infections [2, 3], particularly when atypical
manifestations are present. The clinical manifestations of coinfection
with B. burgdorferi and the agents of HGE, babesiosis, or tick-borne
encephalitis virus have yet to be defined. Until more solid evidence
to the contrary appears, we will assume that if a patient with Lyme
borreliosis has leukopenia or thrombocytopenia, these hematologic
abnormalities are due to an etiology other than infection with
B. burgdorferi (e.g., coinfection with HGE).
This issue is not merely of academic interest but is pertinent to
the choice of antibiotic in the treatment of Lyme borreliosis. Al-
though tetracyclines and some ,B-lactam antibiotics are useful for
treating B. burgdorferi infection, only tetracyclines are clearly ef-
fective in the treatment of HGE and thus should be prescribed (as
Gunthard, et al. did) for patients with possible dual infection.
Robert B. Nadelman, Franc Strle, Harold W. Horowitz,
William A. Agger, and Gary P. Wormser
From the Division of Infectious Diseases, Department ofMedicine, New
York Medical College, and the Lyme Disease Diagnostic Center,
Westchester County Medical Center, Valhalla, New York; the
Department of Infectious Diseases, University Medical Center,
University ofLjubljana, Ljubljana, Slovenia; and the Gundersen Clinic,
La Crosse, Wisconsin
References
1. Gunthard HF, Peter 0, Gubler 1. Leukopenia and thrombocytopenia in a
patient with early Lyme borreliosis, Clin Infect Dis 1996;22:1119-20.
2. Strle F, Nelson JA, Ruzic-Sabljic Ir, et al. European Lyme borreliosis:
231 culture-confirmed cases involving patients with erythema migrans.
Clin Infect Dis 1996;23:61-5. ~.
3. Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum
of early Lyme borreliosis in patients with culture-confirmed erythema
migrans. Am J Med 1996; 100:502-8.
4. Kamp T, Zink C, Beer C, Kaboth W, Nerl C. Agranulozytose durch
infektios-toxische Knochenmarkschadigung nach Borrelien-Infektion.
Dtsch Med Wschr 1995; 120:636-40.
5. Goellner MH, Agger WA, Burgess JH, Duray PH. Hepatitis due to recur-
rent Lyme disease. Ann Intern Med 1988; 108:707-9.
6. Schwartz I, Wormser GP, Schwartz JJ, et al. Diagnosis of early Lyme
disease by polymerase chain reaction amplification and culture of skin
biopsies from erythema migrans lesions. J Clin Microbiol 1992;30:
3082-8.
7. Wormser GP, Horowitz HW, Dumler JS, Schwartz I, Aguero-Rosenfeld
M. False-positive Lyme disease serology in human granulocytic ehr-
lichiosis. Lancet 1996;347:981.
8. Hofmeister EK, Magera J, Sloan L, Kolbert C, Hanson J, Persing DH.
Borrelia burgdorferiproteins are recognized by antibodies from mice
experimentally infected with the agent of human granulocytic ehr-
lichiosis [abstract E814]. In: Program and abstracts of the 7th Interna-
tional Congress on Lyme Borreliosis (San Francisco). 1996.
9. Pancholi P, Kolbert CP, Mitchell PO, et al. Ixodes dammini as a potential
vector of human granulocytic ehrlichiosis. J Infect Dis 1995; 172:
1007-12.
10. Lotric-Furlan S, Strle F. Thrombocytopenia-a common finding in the
initial phase of tick-borne encephalitis. Infection 1995;23:203-6.
The assertions contained herein are the opinions of the authors and do not
necessarily represent the official views of the Centers for Disease Control and
Prevention or the National Institute of Arthritis and Musculoskeletal and Skin
Diseases.
Financial support: Centers for Disease Control and Prevention (Cooperative
Agreements U50/CCU 210286 [R.B.N.] and U50/CCU 2102.80 [G. P. W.])
and the National Institute of Arthritis and Musculoskeletal and Skin Diseases
(ROI-AR41508 [R. B. N., G. P. W.] and ROI-AR43 135 [G. P. W.]).
Reprints or correspondence: Dr. Robert B. Nadelman, Westchester County
Medical Center, Division of Infectious Diseases, Macy Pavilion 209SE, Val-
halla, New York 10595.
Clinical Infectious Diseases 1997;24:1027-8
© 1997 by The University of Chicago. All rights reserved.
1058--4838/97/2405-0062$02.00
Reply
SIR-Nadelman and colleagues comment that although much of
the clinical presentation of our patient was compatible with North
American Lyme borreliosis, it was not typical of the cases seen
in Slovenia. It was not our intention to report a usual clinical
presentation of European Lyme borreliosis. Strle et al. [1] have
reported that 13%-17% of the tick isolates ofBorrelia in Slovenia
have been B. burgdorferi sensu stricto, the same species most
commonly found in the United States. Thus, clinical presentations
similar to those described in the United States may be observed
in Europe, although less frequently. For example, in our region
we see patients with multiple erythema migrans, an unusual finding
in European patients, and we have found that almost 50% of tick
isolates of Borrelia in our region have been found to be B. burg-
dorferi sensu stricto [2].
Nadelman and colleagues seem to have doubts about our diagnosis
of Lyme borreliosis. However, the following findings make us confi-
dent of the diagnosis. First, the expanding lesion in our patient was
a classic erythema migrans. Second, we observed a typical serocon-
version with the screening ELFA (enzyme linked fluorescent assay)
VIDAS Lyme IgG + IgM (biolvlerieux, Marcy l'Etoile, France).
Third, these results were confirmed by an immunoblot assay, which
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at first showed a strong reaction to flagellin, accompanied by a few
others (to p39 in particular); these reactions were followed by a strong
reaction to OspC, which is typically seen in early borrelia infections,
and finally by a complete reaction to > 10 antigens of Borrelia. These
findings fulfilled the Centers for Disease Control and Prevention
criteria for a positive IgG and IgM immunoblot assay.
If this strong reactivity to Borrelia had been caused by cross-
reactivity to Ehrlichia, we would have expected to detect antibod-
ies to E. equi or E. phagocytophila, the Ehrlichia species probably
transmitted by Ixodes ricinus in Switzerland [3]. The two reports
that Nadelman et al. referred to [4, 5] showed that all patients or
mice with ehrlichiosis developed antibodies to Ehrlichia antigens,
as determined by indirect immunofluorescence assay, and then
showed cross-reactivity to B. burgdorferi in an ELISA with equiv-
ocal immunoblots.
We agree with Nadelman and colleagues that leukopenia, thrombo-
cytopenia, and elevated liver enzyme levels are common features in
human ehrlichiosis. This is the reason we sent one serum sample
each (21 and 90 days, respectively, after the beginning ofour patient's
symptoms) to two reference laboratories working with Ehrlichia.
Neither sample showed antibodies to E. equi or E. phagocytophila.
Ofcourse, we are aware ofthe wide range ofpathogens transmit-
ted by I ricinus [6-8]. The other possible pathogens were ex-
cluded by multiple negative serologies for tick-borne encephalitis
as well as by the setting in which the infection occurred and by
the clinical presentation of our patient.
In conclusion, we have nearly ruled out ehrlichiosis and tick-
borne encephalitis and clearly confirmed early Lyme borreliosis
in our patient.
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